Hair loss can be frustrating, especially when you are looking for a treatment that is effective, convenient, and medically sound. TH07 is one of the newest investigational hair loss treatments attracting global attention because it combines three active ingredients into a single topical formula for androgenetic alopecia, also known as male pattern hair loss.
At Derma Clinic, we believe it is important to separate early internet excitement from real clinical evidence. TH07 is highly promising, but it is still under development and has not yet been approved for routine commercial use. Here is a medically grounded look at what TH07 is and what the data reveals.
What Is TH07?
TH07 is a prescription topical treatment being developed by the Canadian biotechnology company Triple Hair Inc. for androgenetic alopecia in men. Instead of relying on a single pathway, it combines minoxidil 5%, finasteride 0.1%, and latanoprost 0.03% into one standardized formulation.
TH07 Ingredients and Their Roles
| Ingredient | Main Role | Why It Matters |
| Minoxidil 5% | Supports hair growth | One of the most established topical treatments for stimulating follicles. |
| Finasteride 0.1% | Helps reduce DHT-related shrinkage | Targets one of the main hormonal causes of male pattern hair loss. |
| Latanoprost 0.03% | May stimulate the active growth phase | A newer prostaglandin analogue showing early promise in hair restoration. |
Each ingredient targets hair loss differently, which is why the combination is generating such strong interest in the dermatology community.
How Does TH07 Work?
Androgenetic alopecia happens when hair follicles gradually become smaller (miniaturize) due to genetic and hormonal factors, especially dihydrotestosterone, or DHT. TH07 is designed to work on multiple pathways at the same time:
- Minoxidil: A well-established vasodilator that helps support follicle activity and hair regrowth by improving blood flow to the scalp.
- Finasteride: Works by reducing the local effects of DHT on the scalp, blocking the major hormone involved in pattern hair loss.
- Latanoprost: A prostaglandin analogue that has shown potential in helping hair follicles remain in or return to the active growth (anagen) phase.
What Does the Research Show?
The most relevant evidence for TH07 comes from a recently published Phase II proof-of-concept pilot study in the International Journal of Trichology. The study reported better hair regrowth with the triple-combination formula than with the individual ingredients used alone. In the trial, over 82% of participants using TH07 experienced positive results.
Evidence Summary
| Finding | What It Suggests | Important Limitation |
| Better regrowth than single ingredients | TH07 may work synergistically and better as a combination. | The Phase II study was small and early-stage. |
| Good tolerance in early study | Topical use may reduce systemic concerns. | Longer safety data across a broader population is still needed. |
| Encouraging early outcomes | TH07 is a promising future option. | It is not yet proven at the same level as approved standard treatments. |
Important Point: TH07 has successfully shown proof-of-concept, but it is currently undergoing larger trials to rigorously test its long-term safety and efficacy.
Is TH07 Approved?
No, TH07 is not yet commercially available for routine prescription use.
Development Status
| Status | Current Situation |
| Regulatory Status | Not yet approved for general market use. |
| Clinical Stage | Under Phase III clinical evaluation. |
| Availability | Not currently available as a standard treatment. |
| Outlook | Future availability depends on trial results and regulatory review. |
Triple Hair Inc. recently hit a major milestone: as of April 2026, the first patient was officially dosed in their pivotal Phase III clinical trials in Canada. This 24-week study will involve 420 men, marking an important step forward. However, the treatment still has a comprehensive regulatory path ahead before it can become widely available.
Possible Side Effects
Because TH07 is a topical application rather than an oral pill, it significantly reduces systemic exposure to the active ingredients—particularly finasteride. That is one reason it is attracting so much clinical interest.
Possible Side Effects
| Type of Side Effect | Examples |
| Local Side Effects | Scalp irritation, dryness, itching, or redness at the application site. |
| Systemic Concerns | Systemic absorption is drastically reduced compared to oral finasteride, and no sexual dysfunction was reported in Phase II. However, long-term Phase III data is still needed. |
As with any prescription hair loss treatment, patients should speak with a qualified dermatologist before starting therapy.
TH07 vs. Standard Hair Loss Treatments
TH07 is based on ingredients already used in hair loss care, but the novelty lies in combining them into one standardized topical formula.
Comparison with Common Treatments
| Treatment | Status | Main Use | Notes |
| Topical Minoxidil | Standard treatment | Supports hair regrowth | One of the most established first-line options. |
| Oral Finasteride | Standard treatment | Reduces DHT systemically | Highly effective, but some patients worry about systemic side effects. |
| Topical Finasteride | Growing evidence | Reduces DHT locally | Lowers systemic exposure; still being actively studied and refined. |
| TH07 | Investigational | Multi-target therapy | Synergistic approach; not yet approved for routine use. |
Who May Benefit in the Future?
If TH07 is eventually approved, it may be a highly useful option for men with androgenetic alopecia who want a single, topical application that attacks hair loss through multiple mechanisms. It will be particularly interesting to patients who prefer to minimize oral medication exposure while still effectively addressing DHT-related hair loss.
Dermatologist’s Advice for Managing Hair Loss Today
The absolute best results in hair loss treatment come from early diagnosis and early intervention.
When to See a Dermatologist
| Situation | Why It Matters |
| Sudden hair shedding | May indicate a different underlying medical cause than pattern hair loss. |
| Receding hairline | Early treatment is the most effective way to preserve existing hair. |
| Thinning at the crown | A hallmark early sign of androgenetic alopecia. |
| Family history of hair loss | Greatly increases your genetic predisposition for pattern hair loss. |
| Failed OTC treatments | You likely need a stronger, prescription-based, or procedural medical plan. |
At Derma Clinic, we recommend a personalized approach based on your specific type of hair loss, age, degree of shedding, medical history, and treatment goals.
FAQs
Is TH07 available now?
No. TH07 is currently heavily engaged in Phase III clinical development and is not yet available for routine prescription use.
Does TH07 cure hair loss?
No treatment currently cures androgenetic alopecia permanently. TH07 is being studied as a highly effective way to improve regrowth and slow the progression of hair loss, but like all genetic hair loss treatments, it requires continuous use to maintain results.
Is TH07 better than minoxidil alone?
Early Phase II data suggests the triple combination performs significantly better than any of the individual ingredients used alone, but the sample size was small. The ongoing Phase III trials will provide a more definitive answer.
Will TH07 be expensive?
Official pricing has not been announced yet, as the drug is years away from hitting the market.
Final Thoughts
TH07 is an exciting investigational treatment for male pattern hair loss because it combines minoxidil, finasteride, and latanoprost in one multi-targeted topical formula. Early results are highly encouraging, but the treatment is still under clinical evaluation and is not yet available for routine use.
If you are noticing thinning hair, do not wait for the “next big treatment” to arrive. Preserving the hair you have is much easier than regrowing what is gone. Book a consultation with us at Derma Clinic in Kathmandu today so we can thoroughly assess your hair loss and create a comprehensive treatment plan based on proven, currently available evidence.
References
- TH07 – A New Novel Topical Treatment for Androgenic Alopecia. International Journal of Trichology. https://pmc.ncbi.nlm.nih.gov/articles/PMC11588191/
- Triple Hair Doses First Patient in Phase III Clinical Trial in Canada for Male Androgenic Alopecia. https://www.businesswire.com/news/home/20260402104876/en/Triple-Hair-Doses-First-Patient-in-Phase-III-Clinical-Trial-in-Canada-f
- Guidelines based management of androgenetic alopecia. https://cosmoderma.org/guidelines-based-management-of-androgenetic-alopecia/
- Triple Hair Clinical Study Featured in Peer-Reviewed Scientific Journal. https://triplehair.ca/th07-clinical-study-featured-in-peer-reviewed-journal/
- Triple Hair Group receives Health Canada approval to start Phase III clinical trials on Therapy-07. https://triplehair.ca/triple-hair-group-receives-health-canada-approval-to-start-phase-iii-clinical-trials-on-its-therapy-07-pre/